Project Grant R01CA292390
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$619K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The federal Project Grant award R35CA283939, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports a research project focused on developing innovative strategies for the treatment of metastatic brain cancer. The $895,779 award to Northwestern University will fund a multi-year effort to: Advance the scientific understanding of how HER2-positive breast cancer metastasizes to the brain by conducting genetic analyses of patient tissue...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584 to The University of Texas MD Anderson Cancer Center to conduct research aimed at understanding the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The key objectives are to: 1) Study the genomic and phenotypic evolution of metastatic precursor cells during dissemination, 2) Investigate gene expression...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct comprehensive research on deciphering the structural determinants of response and resistance to HER2-targeted therapies for HER2-mutant non-small cell lung cancer. The 5-year project aims to 1) characterize the landscape of HER2 mutations associated with response or resistance to tyrosine kinase inhibitors and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to characterize the epigenetic and transcriptional features that drive the dynamic regulation of HER2 expression in breast cancer. The $219,491 award to Emory University, spanning March 2025 to February 2027, will employ cell culture models and single-cell multi-omics analyses to elucidate the mechanisms underlying the rapid conversion between HER2-positive and HER2-low/negative...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,475 to The University of Texas Southwestern Medical Center to develop and validate an in vitro cancer metastasis model system using bioengineered tissue matrices. The goal is to create an organ-specific cancer metastasis model that can better reflect the biology and treatment response of tumor metastasis, which is a critical challenge in cancer research. The researchers...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.396 "Cancer Biology Research" provides $700,690 to Health Research, Inc. at Roswell Park to decipher the molecular mechanisms driving breast cancer bone metastasis. The award aims to understand how the transcriptional coactivators YAP/TAZ regulate metabolic processes in microscopic bone metastases and how this drives the progression to established bone metastases. The researchers will investigate the crosstalk...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $802,230 to the University of Texas Health Science Center at Houston (UTHealth) to conduct research aimed at understanding and overcoming resistance of breast cancer brain metastases to RET inhibition. The key objectives are to: Determine the role of the TGLI1 gene in mediating resistance of breast cancer brain metastases to RET inhibition. Evaluate whether dual targeting of RET and...
This federal Project Grant award for $456,048.00, granted by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at Cold Spring Harbor Laboratory on the mechanisms by which breast cancer disrupts normal circadian rhythms in glucocorticoid hormones. The key objectives are to systematically determine where along the hypothalamic-pituitary-adrenal (HPA) axis the dysfunction occurs in response to breast cancer, identify the underlying...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research to develop and evaluate Antibody-Drug Conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The total funding amount is $215,311 for the period from March 10, 2025 to February 28, 2027. The key objectives are to generate GPR56-targeted ADCs, assess their efficacy and safety in preclinical TNBC models, and evaluate the...
This federal Project Grant award, provided by the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to define the role of the RCOR2 gene in hypoxia-induced immune evasion and its potential therapeutic applications for triple-negative breast cancer. The $1.64 million award, effective from June 1, 2024 through May 31, 2027, will support...